Mon, March 7, 2022

Matthew Harrison Maintained (BLUE) at Sell with Decreased Target to $5 on, Mar 7th, 2022

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -with-decreased-target-to-5-on-mar-7th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Matthew Harrison of Morgan Stanley, Maintained "bluebird bio, Inc." (BLUE) at Sell with Decreased Target from $6 to $5 on, Mar 7th, 2022.

Matthew has made no other calls on BLUE in the last 4 months.



There is 1 other peer that has a rating on BLUE. Out of the 1 peers that are also analyzing BLUE, 0 agree with Matthew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Matthew


  • Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $10 on, Monday, November 8th, 2021